Risk factors

Intense competition in the iCasino and online gaming sector may drive up marketing expenses and depress profit margins.

Rackspace Technology faces substantial ongoing net losses, with $858.2 million lost in fiscal 2024. The business relies heavily on third-party cloud relationships and requires continuous investments that may constrain near-term growth.

RYTHM, Inc. faces heavy regulatory exposure surrounding hemp-derived THC products under the Farm Bill, FDA rules, and the Controlled Substances Act. The company relies significantly on Green Thumb for financial support, debt funding, and shared personnel. Business operations are concentrated in extraction solutions and hemp beverages with limited industry diversification.

Smith Douglas Homes faces intense cyclicality in the Southeastern and Southern US housing markets. Operations rely heavily on trade partners, local land availability, and variable interest rates. Founder and Executive Chairman Tom Bradbury controls 88.1% of combined voting power.

Shoe Station Group relies heavily on key suppliers like Nike and Skechers and a single distribution center in Evansville, Indiana. Comparable store sales for the Shoe Carnival banner have recently declined. Growth depends on omnichannel execution, new store openings, and successful integration of acquisitions.

Soligenix operates with severe going concern doubts, holding only $7.8 million in cash as of December 31, 2024.

This SPAC has no operating history and faces a strict July 11, 2025 liquidation deadline. It has letters of intent with Kneron and a hospitality software company. Risks center on redemption pressure, potential U.S. excise tax, and lack of target details.

Surf Air Mobility faces going concern doubts with $122.6 million in debt and $74.9 million in 2024 losses.

TELA Bio faces ongoing operating losses with an accumulated deficit of $358.7 million as of December 31, 2024. The company has $40.0 million in outstanding debt under its MidCap credit facility maturing in May 2027. Revenue remains highly concentrated in the OviTex product line and heavily dependent on exclusive manufacturer Aroa.

Victoria's Secret & Co. faces intense competition in intimates, reliance on global supply chains in Southeast Asia, and margin pressures from freight, inflation, and consumer spending shifts.

Abeona Therapeutics faces clinical trial, regulatory, and commercialization uncertainties, dominated by risks around securing approval and funding for its lead product pz-cel.

Digital sales represented 37% of total revenue in Fiscal 2024, highlighting omni-channel focus.